Sign In
Buy CABA
$3.58
-0.100 (-2.72%)
At Close: Jun 03, 2026
Cabaletta Bio Reports First Quarter 2020 Financial Results and Provides Business Update
11:00am, Tuesday, 12'th May 2020
Cabaletta Bio, Inc. (CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today
Cabaletta Bio Receives FDA Fast Track Designation for DSG3-CAART for the Treatment of Mucosal Pemphigus Vulgaris
12:00pm, Wednesday, 06'th May 2020
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases
Cabaletta Bio: Curative Medicines For Autoimmunity
06:34pm, Thursday, 30'th Apr 2020
Cabaletta Bio is pioneering the use of CAAR-T cell therapies to potentially cure various autoimmune diseases. Autoimmunity is a large market, at least $100B, bu
New Strong Buy Stocks for April 27th
02:40pm, Monday, 27'th Apr 2020
New Strong Buy Stocks for April 27th
New Strong Buy Stocks for April 27th
02:40pm, Monday, 27'th Apr 2020
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Cubist Systematic Strategies LLC Invests $77,000 in Cabaletta Bio (NASDAQ:CABA)
08:34am, Sunday, 19'th Apr 2020
Cubist Systematic Strategies LLC acquired a new stake in Cabaletta Bio (NASDAQ:CABA) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund acquired 5,505 shares of
Earnings Heat Up And Gold On Display
01:04pm, Saturday, 18'th Apr 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
Cabaletta Bio, Inc. (CABA) Upgraded to Strong Buy: Here's What You Should Know
04:00pm, Friday, 17'th Apr 2020
Cabaletta Bio, Inc. (CABA) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cabaletta Bio's (NASDAQ:CABA) Lock-Up Period To Expire on April 22nd
05:18am, Friday, 17'th Apr 2020
Cabaletta Bio’s (NASDAQ:CABA) lock-up period will end on Wednesday, April 22nd. Cabaletta Bio had issued 6,800,000 shares in its IPO on October 25th. The total size of the offering was $74,800,000 b
Cabaletta Bio's Lock-Up Period Will Expire on April 22nd (NASDAQ:CABA)
05:22am, Wednesday, 15'th Apr 2020
Cabaletta Bio’s (NASDAQ:CABA) lock-up period is set to expire on Wednesday, April 22nd. Cabaletta Bio had issued 6,800,000 shares in its initial public offering on October 25th. The total size of th
Cabaletta Bio Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update
11:00am, Monday, 30'th Mar 2020
DSG3-CAART IND clearance received in October 2019 and Orphan Drug Designation granted by the FDA for the treatment of pemphigus vulgaris (PV) in January 2020; anticipated delay.
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) * Biomerica, Inc. (NASDAQ: BMRA) * Centogene NV (
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 19.)
Biomerica, Inc. (NASDAQ...
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
12:00am, Thursday, 19'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 18)
Biomerica, Inc. (NASDAQ...
Cabaletta Bio to Present at the Cowen and Company 40th Annual Health Care Conference
01:00pm, Thursday, 20'th Feb 2020
PHILADELPHIA, Feb. 20, 2020 -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell.
